冠状动脉介入治疗对冠状动脉粥样硬化性心脏病合并心力衰竭患者血清脑钠肽水平及心功能的影响被引量：3

下载PDF

导出

摘要冠状动脉粥样硬化性心脏病(冠心病)也可称为是缺血性心脏病,经冠状动脉器质性阻塞或狭窄所造成的心肌坏死或心肌缺血缺氧的心脏病.患者疾病的发生密切关联着冠状动脉粥样硬化狭窄支数及程度,诱发此病的关键因素是不良生活习惯、过度肥胖以及高血压、糖尿病等[1,2].因患者心肌受损、冠状动脉血管供血障碍,造成心脏功能及结构的转变,通常会发生心力衰竭.通常会选择保守治疗的方式,经皮冠状动脉介入治疗随着介入治疗技术的不断成熟而获得普及[3].此次研究通过对冠心病合并心力衰竭患者采用冠状动脉介入治疗,现将结果报告如下.

作者张伟河

机构地区河南省嵩县人民医院心内科

出处《实用医技杂志》 2019年第7期878-880,共3页 Journal of Practical Medical Techniques

关键词冠状动脉粥样硬化性心脏病经皮冠状动脉介入治疗心力衰竭血清脑钠肽患者心功能缺血性心脏病心肌缺血缺氧

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1周力,陈晖,李东宝,赵慧强,姚道阔,李虹伟.原发性干燥综合征合并冠心病患者接受冠状动脉介入治疗术后的长期预后分析[J].医学研究杂志,2018,47(11):151-154. 被引量：2
2宗超,唐小霞,张勇.冠心病合并心力衰竭患者经皮冠状动脉介入治疗的早期疗效观察[J].中西医结合心血管病电子杂志,2018,6(20):49-49. 被引量：5
3巩永胜.经皮冠状动脉介入治疗冠心病合并心力衰竭的可行性探讨[J].中西医结合心血管病电子杂志,2017,5(31):41-41. 被引量：6
4宋建敏,陈灿.冠心病合并心力衰竭患者经皮冠状动脉介入治疗的早期疗效观察[J].中国卫生标准管理,2017,8(22):59-61. 被引量：10
5罗秋林,李叶青.冠心病临界病变合并糖调节异常介入治疗的临床观察[J].重庆医学,2016,45(7):966-968. 被引量：2
6李晓烨,王齐兵,胡亚男,吕迁洲.辛伐他汀及阿托伐他汀对冠心病合并糖尿病患者经皮冠状动脉介入术围术期对比剂肾病的预防作用[J].中华临床医师杂志（电子版）,2016,10(21):3170-3175. 被引量：8
7周学才,潘春勤,张博,莫艳霞.冠心病合并左心功能不全患者冠状动脉介入治疗预后影响因素分析[J].医学临床研究,2016,33(6):1126-1128. 被引量：22
8李晓.经皮冠状动脉介入治疗冠心病合并心力衰竭74例临床疗效评价[J].中国卫生产业,2014,11(8):93-94. 被引量：2

二级参考文献47

1胡尔西旦,那斯尔,热依拉.亚合浦.经皮冠状动脉介入治疗冠心病合并心力衰竭68例临床观察及分析[J].医药前沿,2012,12(1):39.
2Haffner SM, Lehto S, R6nnemaa T, et al. Mortality fromcoronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction[J]. N Engl J Med, 1998,339(4) : 229-234.
3National cholesterol education program. The third report of the national cholesterol education program(NCEP)ex- pert panel on detection, evaluation, and treatment of high blood cholesterol in aduhs(aduh treatment panel llI) final report[J]. Circulation,2002,106 (25) :3142-3143.
4Bartnik M, Ryd6n L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary ar- tery disease across europe. The euro heart survey on dia- betes and the heart[J]. Eur Heart J,2004,25 (21): 1880- 1890.
5Obata Y,Yamada Y,Kyo M,et al. Serum adiponectin lev- els predict the risk of coronary heart disease in Japanese patients with type 2 diabetes [J]. J Diabetes Investig, 2013,4(5) :475-482.
6Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory [J]. J Am Coil Cardiol,2007 ,49(8) :839-848.
7Agostoni P, Biondi-Zoceai GG, De Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures;systematic over- view and meta-analysis of randomized trials[J]. J Am Coll Cardiol, 2004,44(2) : 349-356.
8Chaitman BR, Hartigan PM, Booth DC, et al. Do major cardiovascular outcomes in patients with stable ischemic heart disrt in the clinical outcomes utilizing revasculariza- tion and aggressive drug evaluation trial differ by health- care system? [J]. Circ Cardiovasc Qual Outcomes,2010, 3(5) :476-783.
9Courtis J, Rods-Cabau J, Larose E, et al. Comparison of medical treatment and coronary revascuJ.arization in pa- tients with moderate coronary lesions and borderline frac- tional flow reserve measurements[J]. Catheter Cardiovasc Interv, 2008,71 (4) : 541-548.
10Pijls NH,Van Schaardenburgh P,Manoharan G, et al. Pereu- taneous coronary intervention of functionally nonsignificant stenosis:5-year follow-up of the DEFER Study[J]. J Am Coll Cardiol,2007,49(21) :2105-2111.